Afatinib versus Erlotinib as Second-line Treatment Phase III Clinical Trial Update

  • FLASCO
  • July 23, 2015

Afatinib versus Erlotinib as Second-line Treatment Phase III Clinical Trial Update

Boehringer Ingelheim Pharmaceuticals, Inc. would like to share the overall survival (OS) data from a head-to-head Phase III clinical trial that was recently published in The Lancet Oncology. The study evaluated the company’s lung cancer treatment as a potential option for patients with advanced squamous cell carcinoma (SCC) of the lung. New therapies for this disease are clearly needed as prognosis is typically poor.

The publication is available online here. These data were recently unveiled during an oral presentation at ASCO on May 31 in Chicago, and a press release with more information can be found here.

© 2021 FLASCO | Premium Website Design by The HDG

FLASCO